Friday, 19 Oct 2018

You are here

Zolendronic Acid Benefits Elder Women with Osteopenia

The NEJM reports that zolendronic acid was shown to significantly lower the risk of nonvertebral or vertebral fragility fractures in older women with osteopenia. 

A 6-year, double-blind controlled trial involved 2000 women >65 years old with osteopenia (T score −1.0 to −2.5 at hip or femoral neck) who were randomized to receive four infusions of either zoledronate 5 mg or normal saline (placebo) at 18-month intervals. No additional calcium supplements were provided on top of their normal dietary calcium intake (~1 gr/day). The primary endpoint was the time to first occurrence of a nonvertebral or vertebral fragility fracture.

Older women (mean age: 71±5 years) had a baseline femoral neck T score of −1.6±0.5 and the median 10-year risk of hip fracture of 2.3%.

At the end of 6 years, the overall fragility fracture rate was lower in the zoledronate treated patient (HR 0.63; 95% confidence interval, 0.50 to 0.79; P<0.001). The number of women that would need to be treated to prevent the occurrence of a fracture in 1 woman was 15.

Overall, women treated with zoledronate had a lower risk of nonvertebral fragility fractures (HR 0.66; P=0.001), symptomatic fractures (HR 0.73; P=0.003), vertebral fractures (OR  0.45; P=0.002), and height loss (P<0.001).

There were no atypical femoral fractures or cases of osteonecrosis of the jaw reported in either group. But there was a lower rate of certain adverse events, including cancer (OR 0.67; 95% CI, 0.50 to 0.89), myocardial infarction (OR 0.61), and death (OR 0.65; 95% CI, 0.40 to 1.05), in patients on zolendronic acid.

These data attest to the benefits of zolendronic acid given every 18 months for 6 years with a reduced fracture risk when given to elderly women with osteopenia only.  Prior to this study, there was limited evidence about the benefits of treating elderly at risk women with osteopenia only.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Vitamin D Fails to Improve Bone Health

The current edition of Lancet Diabetes & Endocrinology suggests that neither vitamin D supplementation, nor dose, will improve bone density or prevent fractures in adults. (Citation source:

Neuropathic Like Knee Pain

Fernandez and colleagues have shed further light on a significant subset of patients with knee pain - specifically, those with neuropathic like knee pain (NKP) that includes those with knee pain modified by central and peripheral neurologic dysfunction.

Knee Arthroscopic Surgeries on the Decline

A JAMA Internal Medicine report has shown that the rate of arthroscopic surgery has significantly declined, in an era when arthroplasty and the incidence of osteoarthritis (OA) has increased. (Citation source

Fractures May Lead to Systemic Bone Loss

Researchers at the University of California - Davis have shown that elderly women who had an upper body fracture or multiple fractures had more loss of hip density compared to those who who did not fracture. Systemic bone loss may increase the risk of future fractures. 

Maastricht Study Links Dairy Intake to Osteoarthritis

The Maastricht study explored the potential association between dairy consumption and knee osteoarthritis (OA), and found that higher intake of full-fat dairy and Dutch cheese - but not milk - was significantly associated with the lower risk of knee OA.